Aurinia’s New CEO, Richard Glickman, to Present at Leerink Partners 6th Annual Global Healthcare Conference
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that its newly appointed Chief Executive Officer, Richard M. Glickman and Celia Economides, Associate Vice President, Investor Relations will participate in a Fireside Chat at the Leerink Partners 6th Annual Global Healthcare Conference on February 16th at 11:30am ET. A webcast will be available and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay will also be archived on the site following the event.
About Aurinia
Aurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering from
serious diseases with a high unmet medical need. The company is
currently developing voclosporin, an investigational drug, for the
treatment of lupus nephritis (LN), an inflammation of the kidney caused
by Systemic Lupus Erythematosus (SLE) and represents a serious
progression of SLE. The company is headquartered in Victoria, BC and
focuses its development efforts globally. www.auriniapharma.com.
We Seek Safe Harbor.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170210005554/en/
Investor & Media Contact:
Aurinia Pharmaceuticals Inc.
Celia
Economides
Head of IR & Communications
ceconomides@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.
Released February 10, 2017
